Citations

Clear

5626 citation(s) found for "Anderson, KS".

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, Oladapo , Tan, Winston , Patnaik, Amita , LoRusso, Patricia , Richardson, Debra L. , Naqash, Abdul Rafeh , Lynam, Sarah , Kyriakopoulos, Christos E. , Dowlati, Afshin , Chamberlain, Marc C. , Yeku, Oladapo O , Tan, Winston W., Richardson, Debra L , Kyriakopoulos, Christos E , Naqash, Abdul Rafeh , Barve, Minal , Wang, Judy , Fu, Siqing , Gordon, Michael S. , Hubbard, Joleen M. , Kummar, Shivaani , Winer, Ira Seth

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 13, 2025 | Volume: 13 | Issue: 3 | Pages: e010959

10.1136/jitc-2024-010959 | PMID 40081941 Get It

Background Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC. Methods PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3 mg/kg or PY314 10 mg/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200 mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks. Results 17 patients were enrolled in the PY159 study (median age 67, range 22–77; median prior therapies 6, range 2–18) and 16 patients in PY314 (median age 65.5, range 49–81; median prior therapies 4, range 2–10). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8/16 patients (50%; median 16 weeks, range 9–33), and in PY314, it was stable disease in 8/16 patients (50%; median 12 weeks, range 6–36). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm. Conclusions Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.
Advancing Metastatic Spine Tumor Research: A Review of AO Spine Knowledge Forum Tumor’s Scientific Contributions Derived From the EPOSO Network, 2014-2024
Rutges, Joost , Fehlings, Michael G. , Gokaslan, Ziya L., Rhines, Laurence D. , Sahgal, Arjun , Sciubba, Daniel M. , Schuster, James M. , Weber, Michael H. , Laufer, Ilya , Fisher, Charles G. , Tumor, on the behalf of the AO Spine Knowledge Forum, Rutges, Joost P H J , Fehlings, Michael G , Rhines, Laurence D , Zuckerman, Scott L. , Arnold, Paul M. , Bettegowda, Chetan , Boriani, Stefano , Clarke, Michelle J. , Lazáry, Áron , Tumor, on the behalf of the AO Spine Knowledge Forum

Mayo Clinic

Global Spine Journal | March 12, 2025 | Volume: 15 | Issue: 6 | Pages: 2999-3006

10.1177/21925682251326515 | PMID 40074676 Get It

Study Design Narrative Review. Objectives To summarize the work of the AO Spine Knowledge Forum Tumor, specifically studies from the Epidemiology, Process and Outcomes in Spine Oncology (EPOSO) study. Methods A narrative review of all published manuscripts from the EPOSO study was undertaken. EPOSO represents a multicenter, prospective registry effort across 10 North American and European sites to enroll patients with metastatic disease of the spine. Results The current review summarized all studies from the EPOSO network, divided into the following five sections: (1) quality of life and satisfaction, (2) overall survival, (3) spinal instability, (4) neurologic outcome in patients with metastatic epidural spinal cord compression or radicular pain, and (5) patient and tumor-specific factors. Several important findings were elucidated. Patient evaluation should include SINS, nutritional status, severity and duration of neurologic deficit, extent of metastatic tumor burden, and differentiation of axial from radicular pain. Moreover, SOSGOQ2.0 serves as a useful and validated instrument for patient-reported outcome instrument. Despite the palliative nature of metastatic spine surgery, clear improvement in quality-of-life is seen. Even in patients with short-survival, the remaining weeks and months of life result in improved quality-of-life. Metastatic spine surgery often improves neurologic function, potentially enhancing survival through increased performance status. Conclusions Several noteworthy results have come from the EPOSO network, highlighting important trends in metastatic spine care. The AO Spine Knowledge Forum Tumor has helped advancing metastatic spine tumor research as well as ensure these new findings reach and benefit clinicians and their patients.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75

10.6004/jnccn.2025.0013 | PMID 40073835 Get It

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Gajjar, Amar , Mahajan, Anita , Canan, Liz, Chi, Susan , Cluster, Andrew , Cole, Bonnie , Darlington, Wendy , Dorris, Kathleen , Elster, Jennifer , Franson, Andrea , Helgager, Jeffrey, Lin, Chi , Metrock, Laura, Nanda, Ronica H. , Partap, Sonia , Plant, Ashley , Reynolds, Renée M. , Stearns, Duncan , Storm, Phillip, Wang, Leo D. , Whipple, Nicholas , Zaky, Wafik , McMillian, Nicole R., Ramakrishnan, Swathi , Franson, Andrea , Bale, Tejus , Bowers, Daniel C. , Cohen, Kenneth J. , Coven, Scott L. , Ermoian, Ralph P. , George, Elizabeth , Landi, Daniel B. , Palmer, Joshua D. , Pruthi, Sumit , Wang, Anthony

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 113-130

10.6004/jnccn.2025.0012 | PMID 40073837 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations for diffuse high-grade gliomas and medulloblastomas in children and adolescents. This article summarizes the studies and panel discussion that serve as the rationale for comprehensive care recommendations included in the NCCN Guidelines for Pediatric Central Nervous System Cancers.
Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
Abeykoon, Jithma P. , Perera, Nirosha D. , Gustine, Joshua , Ramirez‐Gamero, Andres , Varettoni, Marzia , Tedeschi, Alessandra , Cavalloni, Chiara, Frustaci, Anna Maria , Pederson, Levi , Zanwar, Saurabh , Kapoor, Prashant , Kyle, Robert A. , Geyer, Susan M. , Ansell, Stephen M. , Paludo, Jonas , Sarosiek, Shayna , Varettoni, Marzia , Frustaci, Anna Maria , Pederson, Levi D , Zanwar, Saurabh S , Habermann, Thomas , Witzig, T.E. , Gertz, Morie A , Treon, Steven , Castillo, Jorge J , Ansell, Stephen M , Paludo, Jonas , Habermann, Thomas M. , Witzig, Thomas E. , Gertz, Morie A. , Treon, Steven P. , Castillo, Jorge J.

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 6 | Pages: 980-986

10.1002/ajh.27663 | PMID 40062689 Get It

ABSTRACT As the treatment paradigm for Waldenström macroglobulinemia (WM) continues to evolve, the debate surrounding the prioritization of depth of response versus disease control as therapeutic goals gains significant relevance. However, the impact of depth of response from fixed‐duration therapy on overall survival (OS) was unclear. This multicenter study evaluated the prognostic impact of depth of response using a landmark survival analysis. A total of 440 patients with WM treated with frontline fixed‐duration regimens were included. Attaining a major response (MaR) was associated with superior outcomes, including significantly longer OS. The estimated 5‐year PFS rates for patients with MaR at 6 months versus not were 50% versus 32%, respectively, p < 0.001, and the estimated 5‐year OS rates for patients with MaR at 6 months versus not were 89% versus 70%, respectively, p < 0.001. In a multivariable analysis, MaR at 6 months was independently associated with superior PFS (HR 0.66, p = 0.007) and OS (HR 0.28, p < 0.001). Similar results were seen when considering deeper responses (CR + VGPR vs. PR). Depth of response at 6 months is an important prognostic marker in WM and an independent predictor of PFS and OS. These results support its utilization as a suitable endpoint in clinical studies in WM.
Phase I Study of Vorinostat and Temsirolimus in Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
Stitzlein, Lea , Baig, Muhammad Usman , Chandra, Joya , McGovern, Suzanne, Paulino, Arnold C. , Ketonen, Leena , Khatua, Soumen , Zaky, Wafik , Stitzlein, Lea M , Paulino, Arnold C , Baig, Muhammad Usman

Mayo Clinic

Pediatric Blood & Cancer | March 11, 2025 | Volume: 72 | Issue: 5 | Pages: No page available

10.1002/pbc.31619 | PMID 40000388 Get It

ABSTRACT Background Diffuse intrinsic pontine glioma (DIPG) carries a poor prognosis with a median survival of less than 12 months. Key molecular features include histone H3 mutation (K27M) and AKT pathway dysregulation. There is currently no curative treatment. Methods This is a Phase I study of vorinostat and temsirolimus in newly diagnosed (Stratum 1) and progressive (Stratum 2) DIPG (NCT02420613). The primary aims are to determine the safety, maximum tolerated dose (MTD), and toxicities. A modified 3 + 3 design was used to establish the MTD, where the first three patients were assigned the first dose level regardless of stratum. Stratum 1 received radiotherapy with vorinostat, followed by up to 10 cycles of vorinostat and temsirolimus. Stratum 2 received up to 12 cycles of vorinostat and temsirolimus. Vorinostat was administered at a fixed dose of 230 mg/m 2 daily on Days 1–8, and temsirolimus was administered on Days 1 and 8 at 25 mg/m 2 (Dose level 1) or 35 mg/m 2 (Dose level 2). Results Six patients were enrolled, three in each stratum. No dose‐limiting toxicity was observed, and most adverse effects were limited to Grades 1 or 2, including fatigue, myelosuppression, hyperlipidemia, hyperglycemia, elevated creatinine, nausea, vomiting, and headache. One patient experienced Grade 3 leukopenia. In the study, the MTD with acceptable toxicity was vorinostat 230 mg/m 2 and temsirolimus 35 mg/m 2 . Conclusions Overall, the combination of temsirolimus and vorinostat is well‐tolerated and safe, prompting the need for larger studies to investigate its efficacy.
Minimal clinical impact of embolization to new territory on outcomes in medium vessel occlusion strokes treated with mechanical thrombectomy: a retrospective multicenter study
Salim, Hamza , Yedavalli, Vivek , Lakhani, Dhairya A. , Milhem, Fathi , Musmar, Basel , Adeeb, Nimer , Faizy, Tobias D. , Daraghma, Motaz , Naamani, Kareem El, Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane , Grewal, Inayat , Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Puri, Ajit S., Dyzmann, Christian , Filipe, João Pedro , Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric, Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Salim, Hamza , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Colasurdo, Marco , Alexandru Radu, Răzvan , Klein, Piers , Ota, Takahiro , Jabbour, Pascal , Siegler, James E , Nguyen, Thanh N , Essibayi, Muhammed Amir , Altschul, David J , Gonzalez, Nestor R , Hecker, Constantin , Marnat, Gaultier , Shaikh, Hamza A , Griessenauer, Christoph J , Liebeskind, David S. , Alexandre, Andrea M , Kalsoum, Erwah , Mendes Pereira, Vitor , Guenego, Adrien , Dmytriw, Adam A , Heit, Jeremy J , Musmar, Basel , Regenhardt, Robert W , Lakhani, Dhairya , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Varela, Ricardo , Naamani, Kareem El , Kühn, Anna Luisa , Ghozy, Sherief , Cancelliere, Nicole M , Rouchaud, Aymeric , Fiehler, Jens , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Klein, Piers , Mowla, Ashkan , Clarençon, Frédéric , Siegler, James E. , Nguyen, Thanh N. , Essibayi, Muhammed Amir , Gory, Benjamin , Hecker, Constantin , Griessenauer, Christoph J. , Pedicelli, Alessandro , Wintermark, Max , Dmytriw, Adam A.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 5, 2025 | Volume: 18 | Issue: 1 | Pages: 186-194

10.1136/jnis-2024-022570 | PMID 40044412 Get It

Background Mechanical thrombectomy (MT) is established as an effective treatment for large vessel occlusion strokes, but its efficacy and safety for medium vessel occlusions (MeVOs) remain less clear. This study examines the impact of periprocedural embolization to a new vascular territory (ENT) on clinical outcomes in patients with MeVO stroke treated with MT. Methods A multicenter, retrospective analysis was conducted using the MAD-MT (Multicenter Analysis of primary Distal medium vessel occlusions: effect of Mechanical Thrombectomy) registry, including 2122 patients with MeVO stroke w­ho underwent MT between September 2017 and July 2023. ENT was defined as filling defects in previously unaffected territories, excluding embolization near the original occlusion, observed on final angiographic runs after retrieval of the primary thrombus. The associations between ENT, procedural variables, and 90-day clinical outcomes were evaluated, including functional independence (modified Rankin Scale (mRS) scores of 0–2), excellent outcomes (mRS 0–1), mortality, and hemorrhagic complications. Results ENT occurred in 2.9% (63/2122) of patients. Longer onset-to-arterial puncture time (adjusted OR 1.03; 95% CI 1.01 to 1.05; P=0.002) and a greater number of passes (adjusted OR 1.15; 95% CI 1.01 to 1.32; P=0.032) were associated with increased ENT risk, while excellent recanalization (thrombolysis in cerebral infarction (TICI) scale score 2c–3) was associated with reduced ENT risk (adjusted OR 0.41; 95% CI 0.23 to 0.72; P=0.002). ENT was not associated with poorer functional independence, mortality, or hemorrhagic complications. Conclusions ENT during MT for MeVO stroke occurs infrequently and does not significantly affect the clinical outcomes. These findings suggest ENT risk should not deter clinicians from performing MT in patients with MeVO. Further prospective studies are needed to validate these results.
Analyzing the Donor Dilemma: Outcomes of Kidney Transplant Recipients From Donors With Positive Blood Cultures Obtained at Organ Procurement
Svoronos, Petros, Acosta, R Alfonso Hernandez , Vijayvargiya, Prakhar , Vaitla, Pradeep , Wynn, J. D. , Parham, Jason, Beam, Elena , Sohail, M. Rizwan , Garrigos, Zerelda Esquer , Hernandez Acosta, R Alfonso , Wynn, James J , Beam, Elena , Sohail, M Rizwan , Esquer Garrigos, Zerelda , Anderson, Christopher D.

Mayo Clinic

Open Forum Infectious Diseases | March 4, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1093/ofid/ofae694 | PMID 40041439 Get It

Abstract Based on expert consensus, the American Society of Transplantation recommends 7–14 days of preventive antibiotic therapy for solid organ transplant recipients from donors with positive blood cultures. We evaluated management and outcomes of kidney transplant recipients from these donors.